Follow-up study of Viaskin Peanut shows significant increase in peanut consumption and treatment benefit in peanut allergic children
DBV Technologies, a clinicalstage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term…
Read more here:
Follow-up study of Viaskin Peanut shows significant increase in peanut consumption and treatment benefit in peanut allergic children
October 5, 2015 · by · in Nutritional News · Tags: allergy, dbv, diet, from-the-first, nutritional counseling, olfus, oncalldiets, support-the-long, technologies, the-first, today-announced, vipes
